Axsome Therapeutics (AXSM) Other Accumulated Expenses (2015 - 2020)

Axsome Therapeutics has disclosed Other Accumulated Expenses across 6 years of filings, most recently posting $1.0 million for Q3 2020.

• Other Accumulated Expenses for Q3 2020 came in at $1.0 million, up 30.12% year-over-year; the trailing twelve-month figure through Sep 2020 was $1.0 million (up 30.12% YoY), and the FY2019 annual result was $683178.0, up 29.98% from the prior year.
• Other Accumulated Expenses came in at $1.0 million for Q3 2020 at Axsome Therapeutics, down from $1.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q2 2020 to a low of $168004.0 in Q2 2016.
• The 5-year median for Other Accumulated Expenses is $531021.0 (2019), against an average of $609610.1.
• Across the five-year window, Other Accumulated Expenses jumped 370.74% in 2016 and plunged 43.33% in 2017, its largest moves.
• Axsome Therapeutics' Other Accumulated Expenses stood at $587339.0 in 2016, then plunged by 43.33% to $332824.0 in 2017, then jumped by 57.93% to $525613.0 in 2018, then increased by 29.98% to $683178.0 in 2019, then jumped by 50.9% to $1.0 million in 2020.
• The last three Other Accumulated Expenses figures came in at $1.0 million (Q3 2020), $1.2 million (Q2 2020), and $1.1 million (Q1 2020), per Business Quant data.